N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

Bibliography

• US Food and Drug Administration: Information about the Products We Regulate. Available from: http://www.fda.gov/cder/drug/default.htm [Last accessed October 6 2008]
   Google Scholar
• Therapeutic Goods Administration: National Drugs and Poisons Schedule Committee. Available from: http://www.tga.gov.au. [Last accessed October 6 2008]
   Google Scholar
• Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993;9:441-9
   PubMed Web of Science ®Google Scholar
• Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52:1176-93; discussion 1193-1177
   PubMed Web of Science ®Google Scholar
• Tirouvanziam R, Conrad CK, Bottiglieri T, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006;103:4628-33
   PubMed Web of Science ®Google Scholar
• Selvan VA, Calvert SH, Cavell G, et al. Weight-based N-acetylcysteine dosing chart to minimise the risk of calculation errors in prescribing and preparing N-acetylcysteine infusions for adults presenting with paracetamol overdose in the emergency department. Emerg Med J 2007;24:482-4
   PubMed Web of Science ®Google Scholar
• Mims Online: Prescribing information. Available from: http://mims.hcn.net.au.
   Google Scholar
• Knudsen TT, Thorsen S, Jensen SA, et al. Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects. Gut 2005;54:515-21
   PubMed Web of Science ®Google Scholar
• Mardikian PN, LaRowe SD, Hedden S, et al. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:389-94
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder – a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:468-75
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64(5):361-8
   PubMed Web of Science ®Google Scholar
• Pendyala L, Creaven PJ. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev 1995;4:245-51
   PubMed Web of Science ®Google Scholar
• Holdiness MR. Clinical Pharmokinetics of N-acetylcysteine. Clin Pharmacokinet 1991;20:123-34
   PubMed Web of Science ®Google Scholar
• Gabard B, Mascher H. Endogenous plasma N-acetylcysteine and single dose oral bioavailability from two different formulations as determined by a new analytical method. Biopharm Drug Dispos 1991;12:343-53
   PubMed Web of Science ®Google Scholar
• Cotgreave IA, Moldeus P. Methodologies for the analysis of reduced and oxidized N-acetylcysteine in biological systems. Biopharm Drug Dispos 1987;8:365-75
   PubMed Web of Science ®Google Scholar
• Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine–a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7:355-9
   PubMed Web of Science ®Google Scholar
• Badaloo A, Reid M, Forrester T, et al. Cysteine supplementation improves the erythrocyte glutathione synthesis rate in children with severe edematous malnutrition. Am J Clin Nutr 2002;76:646-52
   PubMed Web of Science ®Google Scholar
• Griffith OW, Meister A. Glutathione: interorgan translocation, turnover, and metabolism. Proc Natl Acad Sci USA 1979;76:5606-10
   PubMed Web of Science ®Google Scholar
• Dickinson DA, Forman HJ. Glutathione in defense and signaling: lessons from a small thiol. Ann N Y Acad Sci 2002;973:488-504
   PubMed Web of Science ®Google Scholar
• Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med 2008;359:285-92
   PubMed Web of Science ®Google Scholar
• Grandjean EM, Berthet P, Ruffman R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta analysis of published double-blind placebo-controlled clinical trials. Clin Ther 2000;22:209-21
   PubMed Web of Science ®Google Scholar
• Zuin R, Palamidese A, Negrin R, et al. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005;25:401-8
   PubMed Web of Science ®Google Scholar
• Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-κB, and glutathione S-transferase gene expression. J Biol Chem 1996;271:13422-9
   PubMed Web of Science ®Google Scholar
• Aremu DA, Madejczyk MS, Ballatori N. N-acetylcysteine as a potential antidote and biomonitoring agent of methylmercury exposure. Environ Health Perspect 2008;116:26-31
   PubMed Web of Science ®Google Scholar
• Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008;33:166-80
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-13
   PubMed Web of Science ®Google Scholar
• Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk. J Appl Genet 2008;49:267-82
   PubMed Web of Science ®Google Scholar
• McCaddon A, Hudson P, Davies G, et al. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001;12:309-13
   PubMed Web of Science ®Google Scholar
• Dittmann S, Seemuller F, Schwarz MJ, et al. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord 2007;9:63-70
   PubMed Web of Science ®Google Scholar
• Prescott L. Oral or intravenous N-acetylcysteine for acetaminophen poisoning? Ann Emerg Med 2005;45:409-13
   PubMed Web of Science ®Google Scholar
• Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J 1979;2:1097-100
   PubMed Web of Science ®Google Scholar
• Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981;141:380-5
   PubMed Web of Science ®Google Scholar
• Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991;303:1026-9
   PubMed Web of Science ®Google Scholar
• Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997;156:341-57
   PubMed Web of Science ®Google Scholar
• Pierson DJ. Clinical practice guidelines for chronic obstructive pulmonary disease: a review and comparison of current resources. Respir Care 2006;51:277-88
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007;62:652-7
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006;15:105-10
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Myrick H, Hedden S, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007;164:1115-7
   PubMed Web of Science ®Google Scholar
• Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine–glutamate exchange underlie cocaine relapse. Nat Neurosci 2003;6:743-9
   PubMed Web of Science ®Google Scholar
• Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008:1-26
   Google Scholar
• Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008;29:346-51
   PubMed Web of Science ®Google Scholar
• Van Hunsel F, Wauters A, Vandoolaeghe E, et al. Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments. Psychiatry Res 1996;65:159-69
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000;97:137-51
   PubMed Web of Science ®Google Scholar
• Akyol O, Herken H, Uz E, et al. The indices of endongenous oxidative and antioxidative processes in plasma from schizophrenic patients; the possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:995-1005
   PubMed Web of Science ®Google Scholar
• Altuntas I, Aksoy H, Coskun I, et al. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med 2000;38:1277-81
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007;41:523-9
   PubMed Web of Science ®Google Scholar
• Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001;64:43-51
   PubMed Web of Science ®Google Scholar
• Kuloglu M, Atmaca M, Tezcan E, et al. Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder. Neuropsychobiology 2002;46:27-32
   PubMed Web of Science ®Google Scholar
• Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007;38:247-52
   PubMed Web of Science ®Google Scholar
• Dakhale G, Khanzode S, Khanzode S, et al. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004;49:205-9
   PubMed Web of Science ®Google Scholar
• Gergerlioglu HS, Savas HA, Bulbul F, et al. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:697-702
   PubMed Web of Science ®Google Scholar
• Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2007;33:2187-99
   PubMed Web of Science ®Google Scholar
• Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001;57:1515-7
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Weverling GJ, Bossuyt PM, et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559-64
   PubMed Web of Science ®Google Scholar
• De Rosa SC, Zaretsky MD, Dubs JG, et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000;30:915-29
   PubMed Web of Science ®Google Scholar
• Spada C, Treitinger A, Reis M, et al. The effect of N-acetylcysteine supplementation upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals undergoing antiretroviral treatment. Clin Chem Lab Med 2002;40:452-5
   PubMed Web of Science ®Google Scholar
• Treitinger A, Spada C, Masokawa IY, et al. Effect of N-acetyl-L-cysteine on lymphocyte apoptosis, lymphocyte viability, TNF-α and IL-8 in HIV-infected patients undergoing anti-retroviral treatment. Braz J Infect Dis 2004;8:363-71
   PubMedGoogle Scholar
• Grant PR, Black A, Garcia N, et al. Combination therapy with interferon-α plus N-acetyl cysteine for chronic hepatitis C: A placebo controlled double-blind multicentre study. J Med Virol 2000;61:439-42
   PubMed Web of Science ®Google Scholar
• Emet S, Memis D, Pamukcu Z. The influence of N-acetyl-L-cystein infusion on cytokine levels and gastric intramucosal pH during severe sepsis. Crit Care 2004;8:R172-179
   PubMed Web of Science ®Google Scholar
• Spapen HD, Diltoer MW, Nguyen DN, et al. Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: results of a pilot study. Chest 2005;127:1413-9
   PubMed Web of Science ®Google Scholar
• Sener G, Sehirli AO, Ayanoglu-Dulger G. Melatonin protects against mercury(II)-induced oxidative tissue damage in rats. Pharmacol Toxicol 2003;93:290-6
   PubMedGoogle Scholar
• Caylak E, Aytekin M, Halifeoglu I. Antioxidant effects of methionine, α-lipoic acid, N-acetylcysteine and homocysteine on lead-induced oxidative stress to erythrocytes in rats. Exp Toxicol Pathol 2008
   PubMedGoogle Scholar
• Yedjou CG, Tchounwou PB. N-acetyl-L-cysteine affords protection against lead-induced cytotoxicity and oxidative stress in human liver carcinoma (HepG2) cells. Int J Environ Res Public Health 2007;4:132-7
   PubMedGoogle Scholar
• Flora SJ, Flora G, Saxena G, Mishra M. Arsenic and lead induced free radical generation and their reversibility following chelation. Cell Mol Biol (Noisy-le-grand) 2007;53:26-47
   PubMed Web of Science ®Google Scholar
• Nzengue Y, Steiman R, Garrel C, et al. Oxidative stress and DNA damage induced by cadmium in the human keratinocyte HaCaT cell line: role of glutathione in the resistance to cadmium. Toxicology 2008;243:193-206
   PubMed Web of Science ®Google Scholar
• Medved I, Brown MJ, Bjorksten AR, et al. N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. J Appl Physiol 2004;97:1477-85
   PubMed Web of Science ®Google Scholar
• McKenna MJ, Medved I, Goodman CA, et al. N-acetylcysteine attenuates the decline in muscle Na+,K+-pump activity and delays fatigue during prolonged exercise in humans. J Physiol 2006;576:279-88
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006;166:161-6
   PubMed Web of Science ®Google Scholar
• Aitio ML. N-acetylcysteine – passe-partout or much ado about nothing? Br J Clin Pharmacol 2006;61:5-15
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42
   PubMed Web of Science ®Google Scholar
• Dippy JE, Davis SS. Rheological assessment of mucolytic agents on sputum of chronic bronchitics. Thorax 1969;24:707-13
   PubMed Web of Science ®Google Scholar
• Mant TG, Tempowski JH, Volans GN, Talbot JC. Adverse reactions to acetylcysteine and effects of overdose. Br Med J (Clin Res Ed) 1984;289:217-9
   PubMed Web of Science ®Google Scholar
• Sarnstrand B, Jansson AH, Matuseviciene G, et al. N,N′-Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. J Pharmacol Exp Ther 1999;288:1174-84
   PubMed Web of Science ®Google Scholar